Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
- Submitting institution
-
University of Edinburgh
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 64611496
- Type
- D - Journal article
- DOI
-
10.1016/S1470-2045(17)30404-7
- Title of journal
- The Lancet Oncology
- Article number
- -
- First page
- 929
- Volume
- 18
- Issue
- 7
- ISSN
- 1470-2045
- Open access status
- Compliant
- Month of publication
- June
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
23
- Research group(s)
-
A - Cancer
- Citation count
- 31
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The submitted member of staff to whom the output is attributed is identified as the first and corresponding author.
- Non-English
- No
- English abstract
- -
